Home/Filings/4/0001179110-20-002272
4//SEC Filing

Contreras Jaime 4

Accession 0001179110-20-002272

CIK 0000001800other

Filed

Feb 24, 7:00 PM ET

Accepted

Feb 25, 5:20 PM ET

Size

11.1 KB

Accession

0001179110-20-002272

Insider Transaction Report

Form 4
Period: 2020-02-21
Contreras Jaime
Senior Vice President
Transactions
  • Award

    Common shares without par value

    2020-02-21+11,25045,956 total
  • Award

    Option (right to buy)

    2020-02-21+68,57868,578 total
    Exercise: $87.72From: 2021-02-21Exp: 2030-02-20Common shares (68,578 underlying)
Holdings
  • Common shares without par value

    (indirect: By Trust)
    22
  • Common shares without par value

    (indirect: By Trust)
    12,081
  • Common shares without par value

    (indirect: By Trust)
    176,217
  • Common shares without par value

    (indirect: By Spouse)
    2,227
Footnotes (7)
  • [F1]These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes.
  • [F2]On May 10, 2019, the reporting person transferred 22,898 directly owned shares to the Jaime Contreras Marvan 2006 Living Trust.
  • [F3]Balance in the Abbott Laboratories Stock Retirement Trust as of February 21, 2020.
  • [F4]Held in the Jaime Contreras Marvan 2006 Living Trust. The reporting person is sole trustee of the trust. The trust is revocable.
  • [F5]The reporting person disclaims beneficial ownership of all securities held by his spouse.
  • [F6]Held in spouse's living trust. The reporting person's spouse is sole trustee of the trust. The Trust is revocable. The reporting person disclaims beneficial ownership of these securities.
  • [F7]Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 22,859 on February 21, 2021, 22,859 on February 21, 2022, and 22,860 on February 21, 2023.

Issuer

ABBOTT LABORATORIES

CIK 0000001800

Entity typeother

Related Parties

1
  • filerCIK 0001587070

Filing Metadata

Form type
4
Filed
Feb 24, 7:00 PM ET
Accepted
Feb 25, 5:20 PM ET
Size
11.1 KB